Practice guidelines for therapeutic drug monitoring of voriconazole: A consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring

Journal of Infection and Chemotherapy

Volumn 19, Issue 3, 2013, Pages 381-392

  Hamada, Yukihiro ^a,q   Tokimatsu, Issei ^b,r   Mikamo, Hiroshige ^a,r   Kimura, Masao ^c,q   Seki, Masafumi ^d,r   Takakura, Shunji ^e,r   Ohmagari, Norio ^f,r   Takahashi, Yoshiko ^g,r   Kasahara, Kei ^h,r   Matsumoto, Kazuaki ^i,r   Okada, Kenji ^j,q   Igarashi, Masahiro ^k,q   Kobayashi, Masahiro ^l,q   Mochizuki, Takahiro ^m,q   Nishi, Yoshifumi ^n,q   Tanigawara, Yusuke ^o,q   Kimura, Toshimi ^j,q   Takesue, Yoshio ^p,r  

^a AICHI MEDICAL UNIVERSITY   (Japan)

^b OITA UNIVERSITY   (Japan)

^c AICHI MEDICAL UNIVERSITY HOSPITAL   (Japan)

^d OSAKA UNIVERSITY   (Japan)

^e KYOTO UNIVERSITY HOSPITAL   (Japan)

^f NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^g HYOGO COLLEGE OF MEDICINE HOSPITAL   (Japan)

^h NARA MEDICAL UNIVERSITY   (Japan)

ⁱ KAGOSHIMA UNIVERSITY   (Japan)

^j TOKYO WOMEN S MEDICAL UNIVERSITY MEDICAL CENTER EAST   (Japan)

^k TORANOMON HOSPITAL   (Japan)

^l KITASATO UNIVERSITY HOSPITAL   (Japan)

^m SHIZUOKA CANCER CENTER   (Japan)

ⁿ KYORIN UNIVERSITY   (Japan)

^o KEIO UNIVERSITY   (Japan)

^p HYOGO COLLEGE OF MEDICINE   (Japan)

^q Sectional Committee of Practice Guidelines for TDM   (Japan)

^r Japanese Society of Chemotherapy   (Japan)

more..

Author keywords

Guideline; Therapeutic drug monitoring; Voriconazole

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ETRAVIRINE; LIVER ENZYME; OMEPRAZOLE; PHENYTOIN; TACROLIMUS; VORICONAZOLE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPERGILLOSIS; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; CANDIDIASIS; CLINICAL TRIAL (TOPIC); CONSENSUS DEVELOPMENT; DOSE LIVER FUNCTION RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDICATION; DRUG INHIBITION; DRUG METABOLISM; DRUG MONITORING; DRUG OVERDOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; GENETIC VARIABILITY; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INVASIVE CANDIDIASIS; LIVER TOXICITY; LOADING DRUG DOSE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MEDICAL SOCIETY; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NEUROLOGIC DISEASE; NONHUMAN; PHARMACODYNAMICS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; STEADY STATE; SYSTEMIC MYCOSIS; VISUAL DISORDER;

EID: 84879248454     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-013-0607-8     Document Type: Article

References (83)

1. Cecil JA, Wenzel RP. Voriconazole: a broad-spectrum triazole for the treatment of invasive fungal infections. Expert Rev Hematol. 2009;2:237-54.
2. Brüggemann RJ, Donnelly JP, Aarnoutse RE, Warris A, Blijlevens NM, Mouton JW, et al. Therapeutic drug monitoring of voriconazole. Ther Drug Monit. 2008;30:403-11.
3. Canadian Task Force on the Periodic Health Examination. The Periodic Health Examination. Can Med Assoc J. 1979;121:1193-254.
4. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol. 2006;46:235-43.
5. Kuo IF, Ensom MHH. Role of therapeutic drug monitoring of voriconazole in the treatment of invasive fungal infections. Can J Hosp Pharm. 2009;62:469-82.
6. Ueda K, Nannya Y, Kumano K, Hangaishi A, Takahashi T, Imai Y, et al. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol. 2009;89:592-9.
7. Trifilio S, Singhal S, Williams S, Frankfurt O, Gordon L, Evens A, et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transpl. 2007;40:451-6.
8. Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother. 2006;50:1570-2.
9. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46:201-11.
10. Okuda T, Okuda A, Watanabe N, Takao M, Takayanagi K. Retrospective serological tests for determining the optimal blood concentration of voriconazole for treating fungal infection. Yakugaku Zasshi. 2008;128:1811-8.
11. Miyakis S, van Hal SJ, Ray J, Marriott D. Voriconazole concentrations and outcome of invasive fungal infections. Clin Microbiol Infect. 2010;16:927-33.
12. Hamada Y, Seto Y, Yago K, Kuroyama M. Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis. J Infect Chemother. 2012;18:501-7.
13. Trifilio S, Pennick G, Pi J, Zook J, Golf M, Kaniecki K, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer (Phila). 2007;109:1532-5.
14. Troke PF, Hockey HP, Hope WW. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother. 2011;55:4782-8.
15. Levin MD, den Hollander JG, van der Holt B, Rijnders BJ, van Vliet M, Sonneveld P, et al. Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms. J Antimicrob Chemother. 2007;60:1104-7.
16. Kakuda TN, Van Solingen-Ristea R, Aharchi F, De Smedt G, Witek J, Nijs S, et al. Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers. J Clin Pharmacol. 2012 [Epub ahead of print].
17. Park WB, Kim NH, Kim KH, Lee SH, Nam WS, Yoon SH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis. 2012;55:1080-7.
18. Yanni SB, Annaert PP, Augustijns P, Ibrahim JG, Benjamin DK Jr, Thakker DR. In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3. Drug Metab Dispos. 2010;38:25-31.
19. Neely M, Rushing T, Kovacs A, Jelliffe R, Hoffman J. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis. 2010;50:27-36.
20. Michael C, Bierbach U, Frenzel K, Lange T, Basara N, Niederwieser D, et al. Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients. Antimicrob Agents Chemother. 2010;54:3225-32.
21. Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother. 2009;53:935-44.
22. Driscoll TA, Yu LC, Frangoul H, Krance RA, Nemecek E, Blumer J, et al. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults. Antimicrob Agents Chemother. 2011;55:5770-9.
23. Driscoll TA, Frangoul H, Nemecek ER, Murphey DK, Yu LC, Blumer J, et al. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults. Antimicrob Agents Chemother. 2011;55:5780-9.
24. Trifilio SM, Yarnold PR, Scheetz MH, Pi J, Pennick G, Mehta J. Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation. Antimicrob Agents Chemother. 2009;53:1793-6.
25. Andes D, Marchillo K, Stamstad T, Conklin R. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother. 2003;47:3165-9.
26. Andes D. Pharmacokinetics and pharmacodynamics in the development of antifungal compounds. Curr Opin Invest Drugs. 2003;4:991-8.
27. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003;36:630-7.
28. Mikus G, Schowel V, Drzewinska M, Rengelshausen J, Ding R, Riedel KD, et al. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther. 2006;80:126-35.
29. Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther. 1996;60:661-6.
30. Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos. 2003;31:540-7.
31. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41:913-58.
32. Kimura M, Yamagishi Y, Kawasumi N, Hagihara M, Hasegawa T, Mikamo H. Clinical implication of therapeutic drug monitoring on voriconazole from the aspect of the analysis for CYP2C19 gene. Jpn J Antibiot. 2010;63:255-64.
33. Purkins L, Wood N, Greenhalgh K, Allen MJ, Oliver SD. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol. 2003;56(suppl 1):10-6.
34. Lazarus HM, Blumer JL, Yanovich S, Schlamm H, Romero A. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol. 2002;42:395-402.
35. Hagiwara E, Shiihara J, Matsushima A, Enomoto T, Tagawa A, Sekine A, et al. Usefulness of monitoring plasma voriconazole concentration in patients with chronic necrotizing pulmonary aspergillosis. Nihon Kokyuki Gakkai Zasshi. 2009;47:93-7.
36. Trifilio S, Ortiz R, Pennick G, Verma A, Pi J, Stosor V, et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transpl. 2005;35:509-13.
37. Matsumoto K, Ikawa K, Abematsu K, Fukunaga N, Nishida K, Fukamizu T, et al. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. Int J Antimicrob Agents. 2009;34:91-4.
38. Lutsar I, Hodges MR, Tomaszewski K, Troke PF, Wood ND. Safety of voriconazole and dose individualization. Clin Infect Dis. 2003;36:1087-8.
39. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34:563-71.
40. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother. 2002;46:2546-53.
41. Hassan A, Burhenne J, Riedel KD, Weiss J, Mikus G, Haefeli WE, et al. Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring. Ther Drug Monit. 2011;33:86-93.
42. Hoffman HL, Rathbun RC. Review of the safety and efficacy of voriconazole. Expert Opin Invest Drugs. 2002;11:409-29.
43. Purkins L, Wood N, Kleinermans D, Greenhalgh K, Nichols D. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol. 2003;56(suppl 1):17-23.
44. Abel S, Allan R, Gandelman K, Tomaszewski K, Webb DJ, Wood ND. Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects: two prospective, multicentre, open-label, parallel-group volunteer studies. Clin Drug Invest. 2008;28:409-20.
45. FDA Antiviral Drugs Advisory Committee - Briefing document for voriconazole (oral and intravenous formulations). http://www.fda.gov/ohrms/ dockets/ac/01/briefing/3792b2-01-Pfizer.pdf.
46. Background Document for the Antiviral Drug Products Advisory Committee Meeting. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2-02-FDA- voriconazole.htm.
47. von Mach MA, Burhenne J, Weilemann LS. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin Pharmacol. 2006;18(6):6.
48. Hafner V, Czock D, Burhenne J, Riedel KD, Bommer J, Mikus G, et al. Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration. Antimicrob Agents Chemother. 2010;54:2596-602.
49. Peng LW, Lien YH. Pharmacokinetics of single, oral-dose voriconazole in peritoneal dialysis patients. Am J Kidney Dis. 2005;45:162-6.
50. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646-9.
51. Cota JM, Burgess DS. Antifungal dose adjustment in renal and hepatic dysfunction: pharmacokinetic and pharmacodynamic considerations. Curr Fungal Infect Rep. 2010;4:120-8.
52. Fuhrmann V, Schenk P, Jaeger W, Miksits M, Kneidinger N, Warszawska J, et al. Pharmacokinetics of voriconazole during continuous venovenous haemodiafiltration. J Antimicrob Chemother. 2007;60:1085-90.
53. Weiler S, Zoller H, Graziadei I, Vogel W, Bellmann-Weiler R, Joannidis M, et al. Altered pharmacokinetics of voriconazole in a patient with liver cirrhosis. Antimicrob Agents Chemother. 2007;51:3459-60.
54. Goutelle S, Larcher R, Padoin C, Mialou V, Bleyzac N. Oral voriconazole dose in children: one size does not fit all. Clin Infect Dis. 2010;51:870 author reply 871.
55. Bruggemann RJ, van der Linden JW, Verweij PE, Burger DM, Warris A. Impact of therapeutic drug monitoring of voriconazole in a pediatric population. Pediatr Infect Dis J. 2011;30:533-4.
56. Ito S, Ishizaki J, Koshiba M, Igarashi Y, Nagata N, Suga Y, et al. Comparison of relationship between dosage and serum concentration of voriconazole in adult and pediatric patients. Iryoyakugaku. 2010;36:213-9.
57. Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother. 2004;48:2166-72.
58. Wood N, Tan K, Purkins L, Layton G, Hamlin J, Kleinermans D, et al. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol. 2003;56(suppl 1):56-61.
59. Purkins L, Wood N, Ghahramani P, Love ER, Eve MD, Fielding A. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Br J Clin Pharmacol. 2003;56(suppl 1):37-44.
60. Takashima M, Taniguchi R, Yano L, Kono T, Hashida T, Masuda S, et al. Pharmacokinetic interactions between calcineurin inhibitors and azole antifungals in hematopoietic stem cell transplant recipients. Jpn J Pharm Health Care Sci. 2009;35:233-9.
61. Trifilio SM, Scheetz MH, Pi J, Mehta J. Tacrolimus use in adult allogeneic stem cell transplant recipients receiving voriconazole: preemptive dose modification and therapeutic drug monitoring. Bone Marrow Transpl. 2010;45:1352-6.
62. Mori T, Aisa Y, Kato J, Nakamura Y, Ikeda Y, Okamoto S. Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transpl. 2009;44:371-4.
63. Kawazoe H, Takiguchi Y, Tanaka H, Fukuoka N, Ohnishi H, Ishida T, et al. Change of the blood concentration of tacrolimus after the switch from fluconazole to voriconazole in patients receiving allogeneic hematopoietic stem cell transplantation. Biol Pharm Bull. 2006;29:2528-31.
64. Xiong X, Duan J, Zhai S, Wang L, Lan X. Fast and reliable determination of voriconazole in human plasma by LC-APCI-MS/MS. Biosci Biotechnol Biochem. 2010;74:2151-3.
65. Wu XJ, Dong XY, Chen YJ, Zhang J, Shi YG, Wu JF, et al. A HPLC method for voriconazole therapeutic drug monitoring. Chin J Infect Chemother. 2009;9:118-22.
66. Wenk M, Droll A, Krahenbuhl S. Fast and reliable determination of the antifungal drug voriconazole in plasma using monolithic silica rod liquid chromatography. J Chromatogr B Anal Technol Biomed Life Sci. 2006;832:313-6.
67. Vogeser M, Schiel X, Spohrer U. Quantification of voriconazole in plasma by liquid chromatography-tandem mass spectrometry. Clin Chem Lab Med. 2005;43:730-4.
68. Vogeser M. The use of HPLC-tandem mass spectrometry in therapeutic drug monitoring. Laboratoriums Medizin. 2005;29:278-86.
69. Verdier MC, Bentue-Ferrer D, Tribut O, Bellissant E. Liquid chromatography-tandem mass spectrometry method for simultaneous quantification of four triazole antifungal agents in human plasma. Clin Chem Lab Med. 2010;48:1515-22.
70. Theurillat R, Zimmerli S, Thormann W. Determination of voriconazole in human serum and plasma by micellar electrokinetic chromatography. J Pharm Biomed Anal. 2010;53:1313-8.
71. Spriet I, Annaert P, Meersseman P, Hermans G, Meersseman W, Verbesselt R, et al. Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation. J Antimicrob Chemother. 2009;63:767-70.
72. Perea S, Pennick GJ, Modak A, Fothergill AW, Sutton DA, Sheehan DJ, et al. Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma. Antimicrob Agents Chemother. 2000;44:1209-13.
73. Pehourcq F, Jarry C, Bannwarth B. Direct injection HPLC micro method for the determination of voriconazole in plasma using an internal surface reversed-phase column. Biomed Chromatogr. 2004;18:719-22.
74. Pascual A, Nieth V, Calandra T, Bille J, Bolay S, Decosterd LA, et al. Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods. Antimicrob Agents Chemother. 2007;51:137-43.
75. Nakagawa S, Suzuki R, Yamazaki R, Kusuhara Y, Mitsumoto S, Kobayashi H, et al. Determination of the antifungal agent voriconazole in human plasma using a simple column-switching high-performance liquid chromatography and its application to a pharmacokinetic study. Chem Pharm Bull (Tokyo). 2008;56:328-31.
76. Michael C, Bierbach U, Frenzel K, Lange T, Basara N, Niederwieser D, et al. Determination of saliva trough levels for monitoring voriconazole therapy in immunocompromised children and adults. Ther Drug Monit. 2010;32:194-9.
77. Lin SC, Lin SW, Chen JM, Kuo CH. Using sweeping-micellar electrokinetic chromatography to determine voriconazole in patient plasma. Talanta. 2010;82:653-9.
78. Gordien JB, Pigneux A, Vigouroux S, Tabrizi R, Accoceberry I, Bernadou JM, et al. Simultaneous determination of five systemic azoles in plasma by high-performance liquid chromatography with ultraviolet detection. J Pharm Biomed Anal. 2009;50:932-8.
79. Farowski F, Cornely OA, Vehreschild JJ, Hartmann P, Bauer T, Steinbach A, et al. Quantitation of azoles and echinocandins in compartments of peripheral blood by liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother. 2010;54:1815-9.
80. Decosterd LA, Rochat B, Pesse B, Mercier T, Tissot F, Widmer N, et al. Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin. Antimicrob Agents Chemother. 2010;54:5303-15.
81. Chhun S, Rey E, Tran A, Lortholary O, Pons G, Jullien V. Simultaneous quantification of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection. J Chromatogr B Anal Technol Biomed Life Sci. 2007;852:223-8.
82. Chahbouni A, Wilhelm AJ, den Burger JC, Sinjewel A, Vos RM. Validated liquid chromatography-tandem mass spectroscopy method for the simultaneous quantification of four antimycotic agents in human serum. Ther Drug Monit. 2010;32:453-7.
83. Alffenaar JW, Wessels AM, van Hateren K, Greijdanus B, Kosterink JG, Uges DR. Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC/MS/MS. J Chromatogr B Anal Technol Biomed Life Sci. 2010;878:39-44.